paclitaxel has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (52.08) | 18.2507 |
| 2000's | 21 (43.75) | 29.6817 |
| 2010's | 2 (4.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CW; Cheng, AL; Chiang, CT; Feng, WC; Gao, M; Hsu, CH; Kuo, SH; Lu, YS; Yeh, LC; Yeh, PY | 1 |
| Backes, M; Bode-Erdmann, S; Greulich, S; Hebart, H; Kaufmann, M; Mahrholdt, H; Ong, P; Ott, G; Schumm, J | 1 |
| Alessandrino, PE; Bertolini, A; Collovà, E; Danova, M; Ferrari, S; Porta, C; Riccardi, A; Rovati, B | 1 |
| Abbasi, MR; Sarta, C; Sparano, JA; Wiernik, PH | 1 |
| Davies, JM; Hancock, BW; Hough, RE; Lorigan, PC; Molife, R; Zekri, JM | 1 |
| Sakashita, A; Sato, A; Taguchi, S | 1 |
| Bonavida, B; De Vos, S; Emmanouilides, C; Gan, XH; Jazirehi, AR | 1 |
| Bonavida, B; Jazirehi, AR | 1 |
| Adams, D; Anderson, E; Chao, NJ; DeCastro, C; Foster, T; Gasparetto, C; Gockerman, JP; Long, GD; McGaughey, D; Moore, JO; Niedzwiecki, D; Rizzieri, DA; Sand, GJ; Toaso, B; Vredenburgh, JJ | 1 |
| Alden, M; Borghaei, H; Millenson, M; Padavic-Shaller, K; Rogatko, A; Schilder, R; Smith, MR; Wang, H | 1 |
| Bonavida, B; Chatterjee, D; Goodglick, L; Jazirehi, AR; Vega, MI | 1 |
| Bailey, HH; Jumonville, A; Kahl, BS; Kim, KM; Longo, WL; McGovern, J; Smith, EP; Smith, J; Turman, N; Werndli, J; Williams, EC | 1 |
| Borghaei, H; Smith, M | 1 |
| Fayad, L; Goy, A; Hagemeister, FB; Loyer, E; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Younes, A | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Tiongson, LP; Younes, A | 1 |
| Guang, ZZ; Jiang, WQ; Li, ZM; Liu, ZC; Yang, DJ; Zhou, JM; Zhu, XF; Zhu, ZY | 1 |
| Bates, S; Bryant, G; Chabner, BA; Cheson, BD; Fojo, A; Goldspiel, BR; Jaffe, ES; Regis, J; Steinberg, SM; Wilson, WH | 1 |
| Hagemeister, F; McLaughlin, P; Melnyk, A; Moore, D; North, L; Rodriguez, MA; Romaguera, J; Sarris, A; Swan, F; Younes, A | 1 |
| Cheson, BD | 1 |
| Cabanillas, F; Callendar, D; Hagemeister, F; Mansfield, P; McLaughlin, P; Mesina, O; Moore, D; North, L; Rodriguez, MA; Romaguera, J; Sarris, AH; Swan, F; Younes, A | 1 |
| Arron, J; Bearman, SI; Cagnoni, PJ; Day, T; Dufton, C; Hami, L; Jones, RB; Martinez, C; Matthes, S; Purdy, MH; Shpall, EJ; Stemmer, SM; Taffs, S | 1 |
| Ayoub, JP; Cabanillas, F; Hagemeister, FB; Martin, J; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Sarris, A; Swan, F; Younes, A | 1 |
| Heinz, R; Hopfinger, G; Pfeilstöcker, M; Pittermann, E; Schlögl, E; Waldner, R | 1 |
| Markman, M | 1 |
| Bearman, SI; Cagnoni, PJ; Jones, RB; Matthes, S; Ross, M; Shpall, EJ; Taffs, S | 1 |
| Ayoub, JP; Bachier, C; Cabanillas, F; Hagemeister, F; Kurzrock, R; McLaughlin, P; North, L; Pate, O; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, A; Smith, T; Younes, A | 1 |
| Bachier, C; Cabanillas, F; Hagemeister, FB; McLaughlin, P; North, L; Pate, O; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, AH; Younes, A | 1 |
| Barcos, M; Budman, DR; Cooper, MR; Johnson, JL; Peterson, BA; Petroni, GR; Schlossman, DM | 1 |
| Balcerzak, SP; Chapman, RA; Fisher, RI; Gagnet, S; LeBlanc, M; O'Rourke, TJ; Press, OW | 1 |
| Chase, EM; Dalton, WS; Dorr, R; Lam, KS; Miller, TP; Salmon, SE | 1 |
| Younes, A | 2 |
| Bachier, C; Cabanillas, F; Hagemeister, F; McLaughlin, P; Mesina, O; Preti, HA; Rodriguez, MA; Romaguera, J; Sarris, AH; Younes, A | 1 |
| Ohnishi, K; Ohno, R | 1 |
| Armand, JP; Couteau, C | 1 |
| Bachier, C; Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, H; Rodriguez, MA; Romaguera, JE; Sarris, AH; Weber, D; Younes, A | 1 |
| Cabanillas, F | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, J; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A | 1 |
| Lyerly, HK; Morse, MA; Vredenburgh, JJ | 1 |
| King, K; Younes, A | 1 |
| Blay, JY; Bouabdallah, K; Caillot, D; Casasnovas, RO; Dumontet, C; Gabarre, J; Gisselbrecht, C; Haioun, C; Lederlin, P; Morel, P; Quesnel, B; Richard, B; Stamatoullas, A | 1 |
| Andrews, DF; Gilmore, GL; Lister, J; Shadduck, RK; Zeigler, ZR | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Mascolini, M | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Palmer, JL; Preti, HA; Rodriguez, MA; Romaguera, JE; Samuels, BI; Younes, A | 1 |
| Goldwasser, F; Misset, JL | 1 |
| Baba, H; Hoffmeier, A; Kamanabrou, D; Roos, N; Rothenburger, M; Scheld, HH; Schmidt, C; Semik, M | 1 |
| Alexopoulou, A; Deutsch, M; Dourakis, SP; Sevastianos, VA; Stavrianeas, N | 1 |
8 review(s) available for paclitaxel and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
[Hypersensitivity reactions to cancer chemotherapeutic agents].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cisplatin; Drug Eruptions; Drug Hypersensitivity; Fever; Histamine H1 Antagonists; Humans; Lymphoma, Non-Hodgkin; Neoplasms; Paclitaxel; Respiration Disorders; Rituximab; Trastuzumab | 2003 |
New chemotherapeutic agents for the treatment of low-grade non-Hodgkin's lymphomas.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Depsipeptides; Gallium; Humans; Lymphoma, Non-Hodgkin; Mitoguazone; Paclitaxel; Peptides, Cyclic; Suramin | 1993 |
[New antitumor drugs for non-Hodgkin's lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Paclitaxel; Prednisone; Rituximab; Taxoids; Vincristine | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Paclitaxel-based treatment of lymphoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Paclitaxel | 1999 |
The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Humans; Lymphoma, Non-Hodgkin; Paclitaxel; Salvage Therapy; Topoisomerase I Inhibitors; Topotecan | 1999 |
Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy | 2000 |
[Clinical use of oxaliplatin in solid tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Neoplasms; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Prostatic Neoplasms; Vinblastine; Vinorelbine | 2001 |
25 trial(s) available for paclitaxel and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome; Vidarabine | 2003 |
Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Blood Cell Count; Disease-Free Survival; Docetaxel; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Microcirculation; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Salvage Therapy | 2004 |
Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Recurrence; Survival Rate | 2004 |
Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Drug Resistance; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2005 |
Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Injections, Subcutaneous; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutrophils; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Recurrence; Topotecan; Treatment Outcome | 2006 |
Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Vidarabine | 2006 |
Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.
Topics: Adult; Aged; Disease-Free Survival; Drug Resistance, Multiple; Female; Humans; Infusions, Parenteral; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Palliative Care; Polymerase Chain Reaction; Recurrence; RNA, Messenger | 1995 |
Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Alopecia; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Remission Induction | 1995 |
Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Cross-Over Studies; Cyclosporine; Dexamethasone; Dextropropoxyphene; Diphenhydramine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Membrane Glycoproteins; Middle Aged; Neoplasm Proteins; Paclitaxel; Premedication; Recurrence; Remission Induction | 1996 |
High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis | 1996 |
No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cross-Over Studies; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel | 1996 |
Paclitaxel in the salvage treatment of Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Salvage Therapy | 1996 |
Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel | 1996 |
Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial.
Topics: Adult; Aged; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Recurrence; Treatment Outcome | 1997 |
Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Vidarabine | 1997 |
Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 1997 |
Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Recurrence; Survival Rate | 1998 |
A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Quinine; Recurrence | 1998 |
Paclitaxel for the treatment of lymphoma.
Topics: Bone Marrow Transplantation; Humans; Lymphoma, Non-Hodgkin; Paclitaxel; Treatment Outcome | 1998 |
Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Intradermal; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Recurrence; Treatment Outcome | 1998 |
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1998 |
Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Paclitaxel; Recurrence; Taxoids; Time Factors; Treatment Outcome | 1999 |
Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Anemia; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Drug Evaluation; Female; Hemorrhage; Humans; Infections; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Recurrence; Survival Rate; Treatment Outcome | 2000 |
Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutrophils; Paclitaxel; Topotecan; Treatment Outcome | 2001 |
15 other study(ies) available for paclitaxel and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Everolimus; Gemcitabine; Humans; Immunosuppressive Agents; Jurkat Cells; Lymphoma, Non-Hodgkin; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2010 |
Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging.
Topics: Adrenal Cortex Hormones; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Delayed Diagnosis; Diagnostic Errors; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Heart Neoplasms; Hemangiosarcoma; Humans; Ifosfamide; Indazoles; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Myocardium; Paclitaxel; Pericardial Effusion; Pericardiocentesis; Pericarditis; Pericardium; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrimidines; Remission Induction; Sulfonamides; Vincristine | 2012 |
Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Lineage; Combined Modality Therapy; Cyclophosphamide; Dendritic Cells; Epirubicin; Female; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Paclitaxel; Th2 Cells | 2003 |
Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Apoptosis; Apoptotic Protease-Activating Factor 1; bcl-X Protein; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Cytochromes c; DNA Fragmentation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Non-Hodgkin; Paclitaxel; Proteins; Proto-Oncogene Proteins c-bcl-2; Rituximab; Signal Transduction | 2003 |
Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; B-Lymphocytes; bcl-X Protein; Caspases; Cell Cycle; Cell Line, Tumor; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Interactions; G2 Phase; Humans; Immunoblotting; Intracellular Membranes; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Membrane Potentials; Mitochondria; Models, Biological; Multiple Myeloma; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Resveratrol; Stilbenes; Time Factors; Transcription Factor AP-1 | 2004 |
Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Topics: Amino Acid Sequence; Androgen-Binding Protein; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; bcl-X Protein; Cell Line, Tumor; Down-Regulation; Drug Synergism; Humans; Lymphoma, Non-Hodgkin; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Paclitaxel; Phosphatidylethanolamine Binding Protein; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Rituximab; Up-Regulation | 2004 |
Comment on "Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study," by Kahl et al., Cancer Investigation, 2005, 23(1), pp. 13-18.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Paclitaxel | 2005 |
Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin D; Cyclins; Cyclophosphamide; Doxorubicin; Drug Synergism; Etoposide; Gossypol; Humans; Lymphoma, Non-Hodgkin; Paclitaxel; Prednisolone; Tumor Suppressor Protein p53; Vincristine | 2008 |
Eighty-seventh annual meeting of the American Association for Cancer Research. Washington, D,C., 20-24 April 1996.
Topics: Aged; Antineoplastic Agents; Breast; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Genes, p53; Genes, Tumor Suppressor; Humans; Hyperplasia; Leukemia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Research; Survival Rate | 1996 |
A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cells, Cultured; Culture Media, Serum-Free; Cyclophosphamide; Dendritic Cells; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-4; Leukapheresis; Leukocyte Count; Lymphocyte Culture Test, Mixed; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neutropenia; Paclitaxel; Taxoids | 1999 |
Mobilization and transplantation of peripheral blood stem cells.
Topics: Antigens, CD34; Blood Transfusion; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Cytokines; Erythrocytes; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocyte Count; Lymphoma, Non-Hodgkin; Paclitaxel; Platelet Transfusion; Regression Analysis; Retrospective Studies; Transplantation, Autologous | 1998 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Oncologists scout new directions for KS and lymphoma therapies.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Chorionic Gonadotropin; Female; Humans; Isotretinoin; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Mitoguazone; Paclitaxel; Palliative Care; Photochemotherapy; Recurrence; Sarcoma, Kaposi; Uterine Cervical Neoplasms | 1995 |
Coexistence of non-Hodgkin's lymphoma and non-small cell lung carcinoma: diagnosis and treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasms, Second Primary; Paclitaxel; Radiography | 2002 |
Treatment side effects. Case 2. Toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Eruptions; Female; Humans; Lymphoma, Non-Hodgkin; Neutropenia; Paclitaxel; Salvage Therapy; Taxoids; Treatment Outcome | 2002 |